Xencor Inc is a prominent player in clinical-stage biopharmaceuticals that operates globally. It primarily focuses on discovering and developing innovative engineered monoclonal antibodies and cytokine programs for the treatment of cancer, autoimmune disorders and infectious disease.
Working in the biotechnology sector, Xencor stands out for its ground-breaking protein engineering technology. The company's services extend to providing novel therapies for life-threatening and debilitating diseases. While Xencor operates independently, it has a network of strategic partnerships, including Alexion and MorphoSys AG, that enhance the value and potential of its pioneering antibody technology.
Diversify your virtual portfolio by following XNCR shares on eToro.